{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+3&page=20", "query": { "intervention": "Level 3", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 5901, "total_pages": 591, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+3&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+3&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T05:37:09.832Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01555164", "title": "A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" }, { "name": "Placebo to match ranolazine", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo to match metformin", "type": "DRUG" }, { "name": "Diet", "type": "BEHAVIORAL" }, { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 442, "start_date": "2012-06", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-09-23", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 60, "location_summary": "Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more", "locations": [ { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Little Rock", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01555164" }, { "nct_id": "NCT01677572", "title": "Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 197, "start_date": "2012-10-05", "completion_date": "2019-07-31", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 32, "location_summary": "Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677572" }, { "nct_id": "NCT04985500", "title": "ESP/PIF for Sternotomy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cardiac Surgery", "Sternotomy" ], "interventions": [ { "name": "ESP block", "type": "PROCEDURE" }, { "name": "PIF block", "type": "PROCEDURE" }, { "name": "Ultrasound", "type": "PROCEDURE" }, { "name": "Bupivacain", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 225, "start_date": "2021-07-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985500" }, { "nct_id": "NCT02551692", "title": "Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cigarette Smoking" ], "interventions": [ { "name": "Nicotine Patch", "type": "DRUG" }, { "name": "Varenicline", "type": "DRUG" }, { "name": "Placebo Nicotine Patch", "type": "DRUG" }, { "name": "Placebo Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 125, "start_date": "2016-01", "completion_date": "2019-01-07", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551692" }, { "nct_id": "NCT07172971", "title": "Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Duchenne Muscular Dystrophy (DMD)" ], "interventions": [ { "name": "SGLT-2 inhibitor", "type": "DRUG" }, { "name": "SGLT2 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "18 Years", "sex": "MALE", "summary": "8 Years to 18 Years · Male only" }, "enrollment_count": 10, "start_date": "2026-07-01", "completion_date": "2028-02-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07172971" }, { "nct_id": "NCT00579644", "title": "Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Combination of Minocycline and MTX or MTX alone", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "19 Years to 75 Years" }, "enrollment_count": 91, "start_date": "2001-03-28", "completion_date": "2006-05-31", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579644" }, { "nct_id": "NCT04620681", "title": "CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes", "type": "BIOLOGICAL" }, { "name": "Standard of Care Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 19, "start_date": "2021-01-14", "completion_date": "2024-07-20", "has_results": true, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04620681" }, { "nct_id": "NCT02543567", "title": "A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.ZEBOV 5*10^10 viral particles (vp)", "type": "BIOLOGICAL" }, { "name": "Ad26.ZEBOV 2*10^10 (vp)", "type": "BIOLOGICAL" }, { "name": "Ad26.ZEBOV 0.8*10^10 (vp)", "type": "BIOLOGICAL" }, { "name": "MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]", "type": "BIOLOGICAL" }, { "name": "MVA-BN-Filo 5*10^7 Inf. U.", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 525, "start_date": "2015-09-21", "completion_date": "2016-11-29", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 6, "location_summary": "Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Mishawaka", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02543567" }, { "nct_id": "NCT06816992", "title": "ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "EGFR Exon 20 Insertion Mutations", "NSCLC", "EGFR-mutated NSCLC" ], "interventions": [ { "name": "ORIC-114 Dose 1 + amivantamab", "type": "DRUG" }, { "name": "ORIC-114 Dose 2 + amivantamab", "type": "DRUG" }, { "name": "ORIC-114 Dose 3 + amivantamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2025-02-27", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 2, "location_summary": "New York, New York • Fairfax, Virginia", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06816992" }, { "nct_id": "NCT01120834", "title": "Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "azacytidine", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-09", "completion_date": "2016-10-20", "has_results": true, "last_update_posted_date": "2017-04-10", "last_synced_at": "2026-10-23T05:37:09.832Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01120834" } ] }